The Justice Department Is Pulling Back on Prosecuting Corporate Crime
- Investment Opportunities
Peter Lynch- 0
- 5 minutes read
The Trump administration has moved sharply away from charging companies over the wrongdoing of employees, recently closing a string of criminal investigations with lenient resolutions or no charges at all.
In matters involving Alibaba, EagleBank and
Abbott Laboratories, the department declined to charge companies even when prosecutors thought executives or managers were involved in the wrongdoing. In those cases, the department didn’t charge any individuals.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
investment News
Pharmaceuticals,Retail/Wholesale,Etailing,Healthcare/Life Sciences,E-commerce,Online Service Providers,Manufacturing,Retail,Services,Technology,Dragonfly – North America,Dragonfly – World,North America,United States,Corporate Crime/Legal Action,Regulation/Government Policy,Corporate/Industrial News,Political/General News,Crime/Legal Action,Content Types,Factiva Filters,C&E Executive News Filter,C&E Industry News Filter,Risk Topics,Risk Topics – Reputation & Ethics,SYND,WSJ-PRO-WSJ.com,GCAPI,Abbott Laboratories,ABT,LINK:EN|drn:realtime.linkedarticle.DNCO20260718000820,LINK|i3-WP-WSJ-0003741216,LINK|i1-WP-WSJ-0003741216,LINK|i9-WP-WSJ-0003741216,LINK|i4-WP-WSJ-0003741216,LINK|i2-WP-WSJ-0003741216,LINK|i6-WP-WSJ-0003741216,LINK|i7-WP-WSJ-0003741216,LINK|i8-WP-WSJ-0003741216,LINK|i5-WP-WSJ-0003741216,corporate crime,legal action,regulation,government policy,corporate,industrial news,political,general news,crime,wholesale,healthcare,life sciences
